Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO6T4G
|
|||
| Drug Name |
PF-07209960
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Pfzer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-15 (IL15) | Target Info | Activator | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| TNF signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| HTLV-I infection | ||||
| Herpes simplex infection | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| FSH Signaling Pathway | ||||
| Leptin Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| WikiPathways | Cytokines and Inflammatory Response | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04628780) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.